| Identification | Back Directory | [Name]
PQA-18 | [CAS]
1604678-82-1 | [Synonyms]
PQA-18
2-Quinolinecarboxylic acid, 4,8-bis[(3-methyl-2-buten-1-yl)oxy]-, 3-methyl-2-buten-1-yl ester | [Molecular Formula]
C25H31NO4 | [MOL File]
1604678-82-1.mol | [Molecular Weight]
409.52 |
| Chemical Properties | Back Directory | [Boiling point ]
545.702±45.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.075±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
3.055±0.10(predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice[1]. | [in vivo]
PQA-18 (0.5 mg/kg, i.p., three times a week) displays immunosuppressing activity in C57BL/6J mice immunized with NP-CGG, with inhibiting the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens[1].
PQA-18 ointment (100 mg/mouse, contains 0.05%-0.1% PQA-18, three times a week, 17 weeks) improves dermatitis and IgE levels in Nc/Nga mice[1].
| Animal Model: | Male C57BL/6J mice (10 weeks old) immunized by intraperitoneal injection of 50 μg NP-CGG[1] | | Dosage: | 0.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.); three times a week | | Result: | Suppressed the NP-specific responses (IgM, IgG1, and IgG3) in peripheral blood.
Significantly suppressed the number of Foxp3+CD4+CD25+ cells in spleens.
|
| [IC 50]
PAK2: 10 nM (IC50); IL-6; IL4; IL-2 | [References]
[1] Ogura M, et al. Prenylated quinolinecarboxylic acid derivative suppresses immune response through inhibition of PAK2. Biochem Pharmacol. 2016 Apr 1;105:55-65. DOI:10.1016/j.bcp.2016.01.020 |
|
|